Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of PF-07976016 in Healthy and Obese Adults
NCT06106009Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07976016 in obesity (13 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events Following Single Doses, Number of Participants With Clinical Laboratory Abnormalities Following Single Doses and 6 more. Started Oct 2023; status: completed.
02
Drugs
PF-07976016
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06106009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06106009.